Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends.
08:25pm, Tuesday, 01'st Nov 2022
With the Fed signaling oversized rate hikes for longer is the likely trajectory moving forward, it is understandable why investors are looking for stocks to sell rather than stocks to buy. Consumer sp
BURNABY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2
Polarean Imaging says US FDA requests additional information from manufacturing partner of its xenon-129 gas blend drug
04:08am, Thursday, 22'nd Sep 2022
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has announced that the US Food and Drug Administration (FDA) has requested additional information from the manufacturing partner for the company's xenon-1
Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
04:01pm, Thursday, 01'st Sep 2022
BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate
Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q2 2022 Results - Earnings Call Transcript
05:01pm, Wednesday, 10'th Aug 2022
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Exec
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
06:48pm, Tuesday, 09'th Aug 2022
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -12.25% and 91.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency
08:24am, Thursday, 23'rd Jun 2022
Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced new efficacy data supporting the Phase 3 development of XEN1101. XEN1101 rapidly reduced focal onset seizure frequency within one week for all dos
Xenon Pharmaceuticals Shares Drop On Proposed Public Offering
05:31pm, Wednesday, 22'nd Jun 2022
Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced an underwritten public offering of its common shares. Underwriters of the offering will be granted an option for a period of 30 days to purchase an
Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
04:01pm, Wednesday, 01'st Jun 2022
BURNABY, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate i
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates
06:49pm, Tuesday, 10'th May 2022
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 7.89% and 4.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q1 2022 Results - Earnings Call Transcript
06:17pm, Tuesday, 10'th May 2022
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President & Chief Executiv
BURNABY, British Columbia, May 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 20
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
04:01pm, Monday, 25'th Apr 2022
BURNABY, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company today announced that Xenon's management team will
Xenon Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
04:01pm, Monday, 04'th Apr 2022
BURNABY, British Columbia, April 04, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate
Xenon Pharmaceuticals to Present at Stifel 2022 CNS Days
08:01pm, Tuesday, 22'nd Mar 2022 GlobeNewswire Inc.
BURNABY, British Columbia, March 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participat
